• Pharming Group NV PHAR.OQ reported a quarterly adjusted loss of 2 cents​​ per share for the quarter ended March 31, identical to the same quarter last year. The mean expectation of two analysts for the quarter was for a loss of one cent per share. Wall Street expected results to range from -2 cents to -1 cents per share.

• Revenue rose 42.3% to $79.09 million from a year ago; analysts expected $67.74 million.

• Pharming Group NV's reported EPS for the quarter was a loss of 2 cents​.

• The company reported a quarterly loss of $14.72 million.

• Pharming Group NV shares had risen by 7.6% this quarter and lost 10.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 50% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "strong buy"

• Wall Street's median 12-month price target for Pharming Group NV is €1.95

This summary was machine generated from LSEG data May 8 at 07:30 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)